Background
==========

Colorectal cancer (CRC) was shown as the second most common of the leading causes of death from cancer in developed countries \[[@B1]\]. Even though colorectal tumorgenesis is a complex process, epidemiological and experimental data indicate that calcium has a chemopreventive role in the development of CRC \[[@B2]\]. In lactose intolerance (LI), both calcium intake and absorption are decreased \[[@B3],[@B4]\]. In Finnish families, a linkage disequilibrium (LD) analysis showed a 47-kb interval locus in 2q21 chromosome region contributing to the trait of LI. Sequence analysis of this region and subsequent association analyses revealed an association between the clinically and biochemically verified LI and a C/T polymorphism in the position of 13910 of the lactase gene (LCT). The cis-acting element properties of this polymorphism, influencing the LCT gene promoter activity, may -- at least partly -- explain the reduced enzymatic activity of the encoded protein, called lactase or lactose-phlorizin hydrolase (LPH) \[[@B5]\]. Diminished LPH activity will result in LI leading to lactose malabsorption that is accompanied with decreased calcium intake \[[@B3],[@B4]\].

Rasinpera et al. \[[@B6]\] have demonstrated that the CC genotype of the LCT gene is significantly associated with increased risk of colorectal cancer in the Finnish population but not in the British or Spanish subjects. Hungarians originate from the Finn-Ugor tribal family and the incidence of LI is in the same range in both populations (20--35%). Therefore, the potential association between the LCT 13910 C/T polymorphism and CRC in the Hungarian population could be postulated.

Calcium-sensing receptor (CaSR) is one of the key factors on cell surfaces, which by sensing the extracellular calcium concentration in the target organs responds to the changes in calcium level, thus, mediates signals towards the inside of the cell. This process is an important step in calcium homeostasis. A connection has been found between the CaSR A986S (G/T) polymorphism and serum calcium concentrations within the normal range in healthy subjects \[[@B7]\]. In addition, CaSR has a significant role in cell proliferation \[[@B8]-[@B10]\]. Reduced or loss of CaSR expression was observed in undifferentiated primary colon cancer cells compared with normal colonic epithelial cells \[[@B11]\]. Disruption of this ligand/receptor system may contribute to an abnormal differentiation and malignant progression. On the other hand, higher extracellular calcium through the intact CaSR might protect from CRC regulating the differentiation and proliferation of colonic epithelial cells \[[@B8]-[@B10]\]. The A986S polymorphism of the CaSR gene has been suggested to increase the risk of other proliferative disorders such as parathyroid adenoma \[[@B12]\].

In the present study, we aimed to investigate the potential relationship between these polymorphisms and the incidence and/or progression of CRC in the Hungarian population.

Methods
=======

Patients
--------

In our study, we included 538 participants, 278 subjects with primary CRC (130 female and 148 male) and 260 healthy blood donors between 2005 and 2007. Information on clinical characteristics (age at the diagnosis, sex, tumor location, TNM classification, stage groupings of the American Joint Committee on Cancer (AJCC), disease recurrence (locoregional and distant), disease-free survival (DFS), overall survival (OS), serum levels of carcinoembryonic antigen (CEA), alpha1-fetoprotein (AFP), carbohydrate antigen 19-9 (CA19-9), calcium and albumin were abstracted from medical records in oncology centers. Age at the diagnosis was 61 ± 11 years. All CRCs were histologically adenocarcinoma. Follow-up data were obtained at every 6 months. The median follow-up period was 17 months (range 1--20 months) in case of 215 patient (63 patient had no clinical follow-up data). The median DFS was 10 months (range 1--20 months). DFS was calculated for 154 patient (61 patient had metastasis at the time of the diagnosis, thus, these patients were excluded from DFS analysis). Twenty-nine participants died during the observational period. Table [1](#T1){ref-type="table"} contains the clinical and pathological data of the patients. The control group consisted of 260 healthy Caucasian blood donors without history of cancer or any chronic diseases. The enrolment criteria in the control group included the lack of gastrointestinal pain, family history for colorectal cancer and detection of blood in stool.

###### 

Clinical characteristics and tumor parameters of patients according to LCT 13910 C/T and CaSR A986S genotypes

                                                          *LCT 13910 C/T genotypes*   *CaSR A986S genotypes*                                           
  ------------------------------------------------------- --------------------------- ------------------------ ---------- ------------- -------------- ----------
  Age at the diagnosis (year) (mean ± SD)                 60 ± 11                     61 ± 10                  0.54       61 ± 10       62 ± 13        0.64
  Male/female (case number)                               66/59                       54/36                    0.29       112/88        8/7            0.84
  Tumor location (case number)                                                                                 0.71^a^                                 0.40^a^
   Rectum                                                 69                          52                                  111           10             
   Left colon                                             27                          17                                  41            3              
   Right colon                                            29                          21                                  48            2              
  TNM classification (case number)                                                                                                                     
   T1                                                     0                           2                        0.54^b^    2             0              0.22^b^
   T2                                                     25                          13                                  37            1              
   T3                                                     74                          60                                  125           9              
   T4                                                     26                          15                                  36            5              
   N0                                                     36                          25                       0.87^c^    54            7              0.10^c^
   N1                                                     58                          43                                  96            5              
   N2                                                     31                          22                                  50            3              
   M0                                                     88                          66                       0.49       143           11             0.88
   M1                                                     38                          23                                  57            4              
  AJCC stages (case number)                                                                                    0.87^d^                                 0.10^d^
   I                                                      10                          6                                   15            1              
   IIA                                                    13                          10                                  20            3              
   IIB                                                    13                          9                                   19            3              
   IIIA                                                   9                           4                                   13            0              
   IIIB                                                   26                          20                                  44            2              
   IIIC                                                   16                          18                                  32            2              
   IV                                                     38                          23                                  57            4              
  Serum calcium (mmol/L), (mean ± SD)                     2.39 ± 0.12                 2.39 ± 0.11              0.85       2.39 ± 0.11   2.39 ± 0.16    0.91
   Normal range (2.2--2.6)                                                                                                                             
   Female                                                 2.41 ± 0.11                 2.36 ± 0.14              0.038^e^   2.39 ± 0.11   2.43 ± 0.18    0.42
   Male                                                   2.37 ± 0.12                 2.39 ± 0.11              0.23       2.39 ± 0.11   2.35 ± 0.15    0.37
  Adjusted serum calcium (mmol/L), (mean ± SD)            2.30 ± 0.11                 2.30 ± 0.13              0.89       2.29 ± 0.11   2.35 ± 0.17    0.13
   Normal range (2.09--2.54)                                                                                                                           
   Female                                                 2.31 ± 0.12                 2.29 ± 0.11              0.31       2.29 ± 0.11   2.40 ± 0.19    0.036^e^
   Male                                                   2.29 ± 0.10                 2.31 ± 0.14              0.54       2.29 ± 0.12   2.31 ± 0.14    0.89
  Serum CEA (ng/mL), \[median (interquartile range)\]     3.33(25.16)                 3.41(13.61)              0.79       3.34(16.13)   3.01(90.77)    0.89
   Normal range (\< 4.3)                                                                                                                               
  Serum CA19-9 (U/mL), \[median (interquartile range)\]   11.15(92.09)                7.21(26.53)              0.59       9.77(42.66)   6.88(214.75)   0.98
   Normal range (\< 39)                                                                                                                                
  Serum AFP (ng/mL), \[median (interquartile range)\]     3.81(2.23)                  3.43(3.05)               0.58       3.57(2.33)    3.57(6.52)     0.94
   Normal range (\< 13.6)                                                                                                                              

^a^P value designates the association for rectum vs. other tumor site

^b^P value designates the association for T1+T2 vs. T3+T4 stages

^c^P value designates the association for N0 vs. N1+N2 stages

^d^P value designates the association for I-II vs. III-IV stages

^e^The association did not remain significant after adjusting for multiple testing

Detailed data were available only for 215 CRC patients

The A986S polymorphism of the CaSR gene and the 13910 C/T polymorphism of the LCT gene were investigated both in the CRC and control groups. Samples were handled anonymously in accordance with previously established ethical protocols. The study was approved by ethical committee. All subjects gave written informed consent.

Genetic analysis of LCT 13910 C/T and CaSR A986S G/T polymorphisms
------------------------------------------------------------------

Genomic DNA was isolated from EDTA blood using a commercially available kit (Magnesil KF Genomic System, Promega, Madison, WI). LCT 13910 C/T (rs4988235) polymorphism involving a thymine (T) to cytosine (C) nucleotide change is located 13.9 kb upstream of lactase gene (LCT) in intron 13 of the adjacent minichromosome maintenance 6 (MCM6) \[[@B13]\]. It was genotyped with the following sequence of allele specific probes 5\'-ATA AGA TAA TGT AGC CCC TGG C; 5\'-ATA AGA TAA TGT AGT CCC TGG C and primers (forward) 5\'-CTC TGC GCT GGC AAT ACA G and (reverse) 5\'-AAA TGC AAC CTA AGG AGG AGA. The PCR mixture (20 μL) contained 1 μL genomic DNA (50 ng/μL), 0.18 μL primers (100 μmol/L; Sigma-Genosys, Woodlans, Texas), 0.04 μL probes (100 μmol/L; Applied Biosystems, Foster City, CA), 10 μL of TaqMan Universal PCR Assay Mix (Applied Biosystems) and 8.56 μL ultrapure PCR water.

Genotyping for CaSR A986S G/T (rs1801725) was performed by a Taqman Pre-Designed SNP Genotyping Assay (Applied Biosystems) \[[@B14]\]. This genetic variance causes an amino acid change from alanine (A) to serine (S) in the protein sequence. The PCR mixture (20 μL) for CaSR A986S polymorphism contained 1 μL genomic DNA (50 ng/μL), 0.50 μL 40× Taqman Pre-Designed SNP Genotyping Assay (Applied Biosystems), 10 μL of TaqMan Universal PCR Assay Mix (Applied Biosystems) and 8.50 μL ultrapure PCR water.

Probes were labeled at the 5\' end with VIC and FAM for both polymorphisms. Cycling conditions for genotypings comprised an initial cycle at 60°C for 1 min and 95°C for 10 min, followed by 55 cycles at 92°C for 15 s and 60°C for 1 min, and a final step at 60°C for 1 min. The fluorescence intensity of was measured by the 7500 RT-PCR System (Applied Biosystems).

Measurement of biochemical parameters (CEA, AFP, CA19-9, serum calcium and albumin)
-----------------------------------------------------------------------------------

Blood samples were obtained at the time of diagnosis of CRC. Serum tumor markers, such as CEA, AFP and CA19-9 were determined by electro-chemiluminescence immunoassays (Roche Diagnostics, Indianapolis, IN). Intra- and inter-assay coefficients of variation (CV) for all previous assays were below 4.1%, 3.8% and 2.9%, for elevated, normal and low serum concentrations, respectively. Serum calcium and albumin were determined by colorimetric assays (Roche Diagnostics). CVs were below 1.9% and 1.7% for elevated and normal serum concentrations, respectively. Calcium levels were corrected for serum albumin: corrected serum calcium = serum calcium (millimoles per liter)-0.02× \[albumin (grams per liter) -- 40)\].

Statistical analysis
--------------------

In the primary analysis, we separately investigated the association between LCT 13910 C/T or CaSR A986S polymorphisms and disease recurrence and DFS. We examined locoregional and distant recurrences separately in the analysis between disease recurrence and genotypes carried out by binary logistic regression. Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated. The events were defined as distant disease recurrence for the DFS analysis in Kaplan Meier method. The survival factor levels were compared with Log rank test. In the secondary analysis, we investigated the associations between these polymorphisms and OS by Kaplan-Meier method with Log rank test. The events were defined as death for the OS analysis.

In basic statistics, we investigated the association between the polymorphisms and cancer incidence by binary logistic regression. The distributions of the variables were analyzed by Kolmogorov-Smirnov test. Means of continuous variables with normal distribution (age at the time of diagnosis, serum calcium, DFS and OS) were compared among genotypes by analysis of variance. We used Mann-Whitney unpaired t-test or Kruskal-Wallis tests to compare the not normally distributed numerical variables (serum albumin, serum CEA, serum CA19-9, serum AFP) among genotypes. The associations between characteristics variables (gender, tumor location, TNM classification, AJCC stages) and genotypes were investigated by Chi-square test.

Analyzing the effect of LCT 13910 C/T polymorphism, we evaluated CC genotypes vs. TT+TC genotypes based on previous studies \[[@B6],[@B15]\]. Additive, recessive and dominant models were used to test the associations among CaSR A986S genotypes and outcome parameters. The number of risk allele (C allele for LCT 13910 C/T polymorphism and S allele for CaSR A986S polymorphism) was used in Spearman rank correlation to investigate the effect of these two polymorphisms on variables. The Hochberg procedure was used for multiple testing adjustment, and adjusted p \< 0.05 was used as the significant criterion. The results were given as mean ± standard deviation (SD) for parameters with normal distribution or median (interquartile range) for variables without normal distribution. The data were analyzed using the SPSS statistical package (SPSS Inc., Chicago, IL; version 15.0 for Windows).

Results
=======

Genotype frequencies followed the Hardy-Weinberg equilibrium. The distant disease recurrence (during the median 17 months follow-up period) was different in LCT genotypes: a significantly higher CC frequency was seen in patients distant disease recurrence (OR = 4.04; 95% CI = 1.71--9.58; p = 0.006) (Table [2](#T2){ref-type="table"}). Also, the DFS, calculated from distant recurrence, was altered according to genotypes with reduced DFS for patient with LCT CC genotypes (log rank test p = 0.008) (Table [2](#T2){ref-type="table"} and Fig. [1](#F1){ref-type="fig"}). Age of patients was not different in the genotype groups (61 ± 10 years for CC genotype and 60 ± 11 years for TT + TC genotypes, p = 0.54). The locoregional disease recurrence and OS were not associated with LCT 13910 C/T genotypes (Table [2](#T2){ref-type="table"}).

###### 

The disease recurrences and DFS, OS according to genotypes in the patient group

                            *LCT 13910 C/T*^a^   *CaSR A986S*^a^                                      
  ------------------------- -------------------- ----------------- -------------- ------ ------------ ---------
  Distant recurrence        4.04                 1.71--9.58        **0.006**      1.07   0.23--4.33   0.93
  Locoregional recurrence   1.37                 0.49--3.87        0.55           0.63   0.08--5.19   0.66
  DFS                       \-                   \-                **0.008**^b^   \-     \-           0.81^b^
  OS                        \-                   \-                0.44^b^        \-     \-           0.49^b^

^a^The parameter for CC vs. TT+TC genotypes or SS vs. AA+AS genotypes were compared

^b^log rank test p value

![Kaplan-Meyer estimates of LCT 13910 genotypes for DFS in CRC patients. Patients with LCT 13910 CC genotype had worse outcome compared to TC + TT genotypes (log rank test p = 0.008).](1471-2407-8-317-1){#F1}

We observed a 0.05 mmol/L difference in serum calcium level between female patients with CC genotype and with TT/TC genotypes, however it did not remain significant after correction for multiple testing. None of the other investigated laboratory and clinical variables showed any correlations with this LCT polymorphism (Table [1](#T1){ref-type="table"}). Cancer incidence was not influenced by this genetic variation (OR = 1.20; 95% CI = 0.85--1.69; p = 0.30).

CaSR A986S polymorphism did not show any associations with tumor recurrence (distant and locoregional), DFS or OS in recessive (Table [2](#T2){ref-type="table"}) or in additive and dominant models (data were not shown). Examining this polymorphism further, cancer incidence was found to be increased in the recessive model (OR = 4.01; 95% CI = 1.33--12.07; p = 0.042): the homozygous CaSR SS genotype was more frequent in patients than controls. This relationship was not significant when examined in dominant or additive models (data not shown). Also, the frequency of the S allele was significantly higher in CRC patients than in controls (Table [3](#T3){ref-type="table"}).

###### 

Genotype distributions regarding study groups

                                                          *LCT 13910 C/T*                     *CaSR A986S*                                
  ------------------------------------------------------- ------------------- --------------- -------------------- ----------- ---------- -----------
  Genotype distribution (n (%))                                                                                                           
   TT or AA                                               46 (16)             48 (19)                              186 (67)    188 (72)   
   TC or AS                                               119 (43)            117 (45)                             75 (27)     68 (26)    
   CC or SS                                               113 (41)            95 (36)                              17 (6)      4 (2)      
  C or S allele frequency                                 0.62                0.59            0.60                 0.20        0.15       **0.025**
  OR (95% CI)^a^                                          1.20 (0.85--1.69)   0.30            4.01 (1.33--12.07)   **0.042**              
  OR (95% CI) in interaction analysis (C and S alleles)   1.25 (1.03--1.52)   **p = 0.026**                                               

^a^The parameter for CC vs. TT+TC genotypes or SS vs. AA+AS genotypes were compared

Serum calcium concentrations were elevated in female subjects with SS genotype compared to AA/AS genotypes (Table [1](#T1){ref-type="table"}), however, this correlation did not remain significant after correction for multiple testing. Other examined laboratory and clinical variables were not different among CaSR genotypes (Table [1](#T1){ref-type="table"}). Serum calcium levels did not correlate with the survival parameters (DFS, OS, locoregional and distant recurrences in the follow-up period) or other laboratory values.

The number of LCT C and CaSR S risk alleles were associated with increasing tumor incidence (p = 0.035). In addition, the CCSS genotype combination (n = 5) was found only in patients with CRC (p = 0.033). Similar association was not observed with survival parameters (DFS, OS, locoregional and distant recurrences in follow-up period) or laboratory values.

Discussion
==========

In our study, we have found a significant correlation between LCT 13910 C/T polymorphism and the progression of CRC. Rasinpera et al. \[[@B6]\] found that the CC genotype was more frequent in the patient group in the Finnish population. We could not detect this association, however, CC genotype frequency was higher in the Hungarian population in general (patients: 41%, controls: 36%) than that for the Finnish population (patients: 23.5%, controls: 18%). On the other hand, we could show a decreased survival rate in CRC patients with CC genotype. This aspect was not examined in the Finnish study since it had a cross-sectional design. The reduced survival of subjects with CC genotype could not be attributed to the more advanced age of these patients since there was no difference in this respect between genotype groups.

Some authors have demonstrated that the CC genotype is associated with low LPH-specific mRNA expression and LPH activity in intestinal biopsy samples \[[@B16],[@B17]\]. Also, close relationship was observed between the positive result of hydrogen breathing test and CC genotype \[[@B18]\]. Patients with LI consume less milk products, which is the main source of calcium \[[@B3],[@B4]\]. Non-digested lactose in LI can additionally impair calcium absorption further aggravating negative calcium balance \[[@B19]\]. The reduction in calcium absorption can also be seen in subjects with positive breathing test but without clinical symptoms (11--32% of all lactose intolerant patients) \[[@B3],[@B4]\]. In our study, subjects with CC genotype had lower serum calcium, although this correlation disappeared after correcting for multiple testing.

Increased calcium intake may reduce CRC incidence suggesting that calcium could be an important chemopreventive factor in colorectal carcinogenesis \[[@B2],[@B10],[@B20],[@B21]\]. Reduced calcium intake will result in reduced intraluminal calcium concentration, and as a consequence, increased amounts of free bile and fatty acids. Calcium binds to bile and fatty acids, forming insoluble complexes, thus, reducing their free concentrations in the intestinal tract \[[@B22]-[@B24]\]. Free bile and fatty acids may promote carcinogenesis \[[@B24]\]. In addition, calcium itself may inhibit hyperproliferation of colonic epithelial cells \[[@B2],[@B21],[@B25]\].

Digestion of lactose by LPH will produce galactose that may also add to the pathogenetic process leading to the development of CRC, producing lower amount of galactose as enzyme product. One of the most common glycolysation abnormalities in colon cancer is the increased mucosal expression of the galactose-β-1,3-N-acetilgalactosamine, known as the Thomsen-Friedenreich blood group antigen \[[@B26]\]. This compound is able to bind to lectins, known factors of stimulated colon epithelial proliferation. Intestinal galactose produced by LPH enzyme has a protective effect against CRC by binding lectins, thus, inhibiting mucosal proliferation \[[@B27]\]. In LI, i.e. in the presence of CC genotype, the amount of intestinal galactose is decreased due to the insufficient LPH concentration. This mechanism may also contribute to the negative effect of this genotype on CRC progression observed in our study.

The CaSR A986S polymorphism appeared to have an impact on CRC incidence in our study. CaSR serves as a messenger system in controlling calcium homeostasis. CaSR is a G protein-coupled receptor \[[@B28]\] and it is responsible for modulating PTH and calcitonin release in response to alterations in extracellular calcium levels. Also, extracellular calcium concentration inhibits 1,25-dihidroxyvitamin D~3~synthesis in renal proximal cells mediated by CaSR \[[@B29],[@B30]\]. Higher concentration of calcium inhibits the proliferation of cancer cells \[[@B8]-[@B10]\]. In colonic epithelial cell lines, extracellular calcium regulates the differentiation and proliferation via the CaSR \[[@B8]-[@B10]\]. CaSR has been reported most highly expressed in well-differentiated regions of colon cancer and nearly lacking in poorly differentiated sites \[[@B8]\]. CaSR A986S polymorphism causing impaired sensing of extracellular calcium might contribute to the development of colorectal cancer. In this case, elevated extracellular calcium could not act as preventive factor on the altered CaSR. This hypothesis is strengthened by our findings that CaSR SS genotype with reduced calcium-sensing capacity was more frequent in CRC patients.

The stimulation of the CaSR may decrease colorectal carcinogenesis through several mechanisms. It promoted E-cadherin expression, a transmembran glycoprotein that functions in cell-cell adhesion and epithelial integrity \[[@B8]\]. Calcium/CaSR also suppress β-catenin -- T cell factor (TCF) activation, which is responsible for the expression of broad range of malignant effectors, such as c-myc, gastrin, cyclin D1, cyclo-oxigenase-2 (COX-2), matrilysin, urokinase-type plasminogen activator, CD44, multidrug resistence-1 gene and its product P-glycoprotein \[[@B8],[@B31]\]. On the other hand, the activation of CaSR results in cell growth and differentiation control by the mitogen-activated protein kinase (MAPK) system \[[@B10]\]. This stimulation is elicited through filamin-A that is bound to the intracellular region of CaSR containing the A986S mutation site \[[@B32],[@B33]\]. In the mutated CaSR, stimulation of MAPK is impaired, thus, cells may proliferate in an uncontrolled manner. As a proof of this putative mechanism, SS genotype was accompanied with increased risk of CRC in our study.

According to our results, both LCT and CaSR gene polymorphisms appear to affect CRC incidence/progression. The negative effects of LCT C and CaSR S alleles could be additive since the number of copies of these disadvantageous genetic variations was accompanied with increasing incidence of CRC. In addition, CCSS genotype combination was only found in patients with CRC.

The limitations of our study include the relatively short follow-up period of 17 months, as well as the lack of detailed evaluation of calcium consumption. We did not explore underlying mechanisms either that could explain the observed correlations between the LCT/CaSR polymorphisms and the examined factors.

Conclusion
==========

Our results suggest that the LCT 13910 CC genotype may affect tumor recurrence and disease-free survival, while the modified calcium signaling in the CaSR 986 SS genotype could lead to increased incidence of CRC. The importance of these findings requires further investigations.
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